- Nine abstracts accepted, including three oral presentations of ALXN1210 Phase 3 PNH data -
The accepted abstracts are listed below and are now available on the ASH website.
Phase 3 Study of Ravulizumab (ALXN1210) versus Eculizumab in Adults with
Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors:
Results of a Subgroup Analysis with Patients Stratified by Baseline
Hemolysis Level, Transfusion History, and Demographics. Abstract
ID#: 110623 – Oral Presentation,
from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab
(ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal
Hemoglobinuria Currently Treated with Eculizumab.Abstract
ID#: 119147 – Oral Presentation,
(ALXN1210) versus Eculizumab in Adults with Paroxysmal Nocturnal
Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two
Phase 3 Randomized, Multicenter Studies.Abstract ID#:
110858 – Oral Presentation,
Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized
Studies of Ravulizumab (ALXN1210) versus Eculizumab in Adults with
Paroxysmal Nocturnal Hemoglobinuria. Abstract ID#: 110874 –
of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal
Hemoglobinuria in the International PNH Registry. Abstract ID#:
111306 – Poster Presentation,
Benefit of Early In-hospital Diagnosis and Treatment Initiation of
Eculizumab in aHUS.Abstract ID#: 112893 – Poster
Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for
Thrombotic Events in Untreated Patients in the International PNH
Registry. Abstract ID#: 111324 – Poster Presentation,
Baseline Characteristics of Patients with Paroxysmal Nocturnal
Hemoglobinuria Identified in the
The Value of Population Based Data to Study Rare Diseases: An Example
About Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, progressive, debilitating, and potentially life-threatening ultra-rare blood disorder that can strike men and women of all races, backgrounds, and ages without warning, with an average age of onset in the early 30s.1,2,3 PNH often goes unrecognized, with delays in diagnosis ranging from one to more than 10 years.2 In patients with PNH, chronic, uncontrolled activation of the complement system, a component of the body’s immune system, results in hemolysis (the destruction of red blood cells)4, which in turn can result in progressive anemia, fatigue, dark urine, and shortness of breath.5,6,7 The most devastating consequence of chronic hemolysis is thrombosis (the formation of blood clots), which can damage vital organs and cause premature death.8 Historically, it had been estimated that one in three patients with PNH did not survive more than five years from the time of diagnosis.2 PNH is more common among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes (MDS).9,10,11 In certain patients with thrombosis of unknown origin, PNH may be an underlying cause.4
ALXN1210 is an innovative, investigational, long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system that, when activated in an uncontrolled manner, plays a role in severe ultra-rare disorders like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive myasthenia gravis (MG). In Phase 3 clinical studies in complement inhibitor-naïve patients with PNH, and patients with PNH who had been stable on Soliris®, intravenous treatment with ALXN1210 every eight weeks demonstrated non-inferiority to intravenous treatment with Soliris® every two weeks, with numeric results for all primary and key secondary endpoints favoring ALXN1210. ALXN1210 is also currently being evaluated in a Phase 3 clinical study in complement inhibitor-naïve patients with aHUS, administered intravenously every eight weeks. In addition, Alexion plans to initiate a Phase 3 clinical study of ALXN1210 delivered subcutaneously once per week as a potential treatment for patients with PNH and aHUS.
ALXN1210 has received Orphan Drug Designation (ODD) for the treatment of
patients with PNH in the U.S., EU, and
About Soliris® (eculizumab)
Soliris® is a first-in-class complement inhibitor that works by
inhibiting the C5 protein in the terminal part of the complement
cascade, a part of the immune system that, when activated in an
uncontrolled manner, plays a role in severe rare and ultra-rare
disorders like paroxysmal nocturnal hemoglobinuria (PNH), atypical
hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR)
antibody-positive myasthenia gravis (MG). Soliris® is approved in the
Soliris® has received Orphan Drug Designation (ODD) for the treatment of
patients with PNH in the U.S., EU,
For more information on Soliris®, please see full prescribing information for Soliris®, including BOXED WARNING regarding risk of serious meningococcal infection, available at www.soliris.net.
Important Soliris® Safety Information
The U.S. prescribing information for Soliris® includes the following
warnings and precautions: Life-threatening and fatal meningococcal
infections have occurred in patients treated with Soliris®.
Meningococcal infection may become rapidly life-threatening or fatal if
not recognized and treated early. Comply with the most current
Patients may have increased susceptibility to infections, especially with encapsulated bacteria. Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with Soliris® may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenza type b (Hib). Soliris® treatment of patients with PNH should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris® treatment has not been established. Administration of Soliris® may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions.
In patients with PNH, the most frequently reported adverse events observed with Soliris® treatment in clinical studies were headache, nasopharyngitis, back pain, and nausea. In patients with aHUS, the most frequently reported adverse events observed with Soliris® treatment in clinical studies were headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, and pyrexia. In patients with gMG who are anti-AchR antibody-positive, the most frequently reported adverse reaction observed with Soliris® treatment in the placebo-controlled clinical study (≥10%) was musculoskeletal pain.
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the discovery,
development and commercialization of life-changing therapies. As the
global leader in complement biology and inhibition for more than 20
years, Alexion has developed and commercializes the first and only
approved complement inhibitor to treat patients with paroxysmal
nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome
(aHUS), and anti-acetylcholine receptor (AchR) antibody-positive
generalized myasthenia gravis (gMG). Alexion also has two highly
innovative enzyme replacement therapies for patients with
life-threatening and ultra-rare metabolic disorders, hypophosphatasia
(HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the
company is developing two late-stage therapies, a second complement
inhibitor and a copper-binding agent for Wilson disease. Alexion focuses
its research efforts on novel molecules and targets in the complement
cascade and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, and metabolic disorders. Alexion has
been named to the
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties relating to future events and the future
performance of Alexion, including statements related to: the Company
extending its leadership in understanding and treating rare
complement-mediated diseases; future plans to initiate a clinical
studies of ALXN1210 delivered subcutaneously once per week as a
potential treatment for patients with PNH and for studies of ALXN1210
for other indications; and the potential medical benefits of ALXN1210
for the treatment of PNH and other diseases. Forward-looking statements
are subject to factors that may cause Alexion's results and plans to
differ materially from those expected by these forward looking
statements, including for example: our dependence on sales from our
principal product (Soliris®); future competition from
biosimilars and other products; decisions of regulatory authorities
regarding the adequacy of our research, marketing approval or material
limitations on the marketing of our products; delays or failure of
product candidates to obtain regulatory approval; delays or the
inability to launch product candidates due to regulatory restrictions,
anticipated expense or other matters; interruptions or failures in the
manufacture and supply of our products and our product candidates;
failure to satisfactorily address matters raised by the
1 Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007 May;137(3):181-92.
2 Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. NEngl J Med. 1995
3 Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573-577.
4 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985-4996.
5 Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in
6 Weitz I, Meyers G, Lamy T, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013;43:298-307.
7 Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005
8 Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007
9 Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100 (12):3897-3902.
10 Iwanga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102(2):465-474.
11 Maciejewski JP, Rivera C, Kook H, et al. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001;115:1015-1022.
Alexion Pharmaceuticals, Inc.
Arne Naeveke, PhD, 857-338-8597
Susan Altschuller, PhD, 857-338-8788